MedDataX Logo

Simvatstatin Used to Treat Pulmonary Hypertension

NCT ID: NCT00538044

Last Updated: 2007-10-02

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

PHASE1

Study Classification

INTERVENTIONAL

Study Start Date

2009-01-31

Study Completion Date

2012-01-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

we try to use simvastatin in the treatment of advanced pulmoary hypertension secondary to congenital heart disease or chronic pulmonary embolism before and after the operation.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

advanced pulmonary hypertension is refractory to the medication in use nowaday, especially pulmonary hypertension secondary to congenital heart disease or chronic pulmonary embolism.It is revealed that statins may intefere the pathogenisis of the pulmonary hypertension in many key poing, such as improving apotosis or inhiting the proliferation of pulmonary vascular smooth muscle cell. so we try to use simvastatin in the treatment of advanced pulmoary hypertension secondary to congenital heart disease or chronic pulmonary embolism before and after the operation.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hypertension, Pulmonary

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

pulmonary hypertension simvastatin advanced pulmonary hypertension secondary to congenital heart disease advanced pulmonary hypertension secondary to chronic pulmonary embolism

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

SINGLE

Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

1simvastatin group

before the operation, the patient start the simvastatin medication on the dosage of 40mg per day

Group Type EXPERIMENTAL

simvastatin

Intervention Type DRUG

medication with simvastation on the dosage of 40mg per day before the operation and all the time after the operation

2contral group

just do routin operation with no use of simvastatin, other medication is exact the same as the simvastatin group

Group Type NO_INTERVENTION

No interventions assigned to this group

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

simvastatin

medication with simvastation on the dosage of 40mg per day before the operation and all the time after the operation

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* pasp\>50mmHg

Exclusion Criteria

* pasp\<50mmhg
Minimum Eligible Age

12 Years

Maximum Eligible Age

70 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Capital Medical University

OTHER

Sponsor Role lead

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Huili Gan, MD,Ph.D.

Role: STUDY_CHAIR

Beijing Anzehn Hospital

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Beijing Anzhen Hospital

Beijing, , China

Site Status

Countries

Review the countries where the study has at least one active or historical site.

China

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Huili Gan, MD,Ph.D.

Role: CONTACT

Phone: 13001277863

Email: [email protected]

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Huili Gan, MD, Ph.D.

Role: primary

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

Anzhen1

Identifier Type: -

Identifier Source: secondary_id

Gan1

Identifier Type: -

Identifier Source: org_study_id